Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Raltegravir
Drug ID BADD_D01905
Description Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Indications and Usage For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
Marketing Status approved
ATC Code J05AJ01
DrugBank ID DB06817
KEGG ID D06676
MeSH ID D000068898
PubChem ID 54671008
TTD Drug ID D0I1FQ
NDC Product Code 0006-0477; 0006-3603; 50090-1085; 65977-0049; 82982-055; 17381-749; 0006-0227; 53002-1686; 71205-777; 68071-2113; 0006-3080; 0006-0473
UNII 22VKV8053U
Synonyms Raltegravir Potassium | Potassium, Raltegravir | Raltegravir | MK 0518 | 0518, MK | MK0518 | MK-0518 | Isentress
Chemical Information
Molecular Formula C20H21FN6O5
CAS Registry Number 518048-05-0
SMILES CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)O)C(=O)NCC3=CC=C(C=C3)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Respiratory distress22.02.01.0120.002472%-
Respiratory failure14.01.04.003; 22.02.06.0020.002472%
Rhabdomyolysis15.05.05.0020.006922%
Rhinorrhoea22.12.03.0210.005274%
Shock24.06.02.0020.001648%-
Skin exfoliation23.03.07.0030.003626%-
Splenomegaly01.09.02.0010.001648%-
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.0070.001648%
Stillbirth08.04.01.006; 18.01.02.0020.003296%-
Suicidal ideation19.12.01.0030.006592%
Syncope02.11.04.015; 17.02.04.008; 24.06.02.0120.003296%
Thrombocytopenia01.08.01.0020.007416%-
Thrombotic thrombocytopenic purpura01.08.01.005; 23.06.01.011; 24.07.06.0140.001648%
Uterine leiomyoma16.04.02.001; 21.07.02.0040.001648%-
Vomiting07.01.07.0030.032138%
Energy increased08.01.03.0170.005604%-
Ischaemic cardiomyopathy02.04.01.004; 24.04.04.0190.002472%-
Retinal toxicity06.09.03.013; 12.03.01.0360.001648%-
Lipodystrophy acquired14.08.04.008; 23.07.01.0030.002472%-
General physical health deterioration08.01.03.0180.002472%-
Muscle tightness15.05.03.0070.003626%-
Musculoskeletal stiffness15.03.05.0270.003626%-
Foetal death08.04.01.011; 18.01.02.0030.004120%
Toxic skin eruption10.01.01.008; 12.03.01.073; 23.03.05.0030.003296%-
Lung neoplasm malignant16.19.02.001; 22.08.01.0010.001648%-
Drug resistance08.06.01.0050.010218%-
Adverse event08.06.01.0100.043015%-
Feeding disorder14.03.02.003; 19.09.01.0030.001648%-
Inflammation08.01.05.007; 10.02.01.0890.001648%-
Abnormal behaviour19.01.01.0010.001648%-
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene